Is Y-mAbs Therapeutics, Inc. overvalued or undervalued?

As of 25 February 2021, the valuation grade for Y-mAbs Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its financial outlook. The company is currently considered overvalued, as evidenced by its negative P/E ratio and troubling financial metrics. Key ratios include a Price to Book Value of 2.67, an EV to EBITDA of -5.88, and a ROCE of -104.17%, all of which highlight the company's struggles in generating returns.
In comparison to its peers, Y-mAbs has a worse EV to EBITDA ratio than Ocular Therapeutix, Inc. at -5.2132 and Vanda Pharmaceuticals, Inc. at 1.1136, both of which are also classified as risky. The company's stock performance has been notably poor, with a year-to-date return of -39.72%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. This combination of negative financial ratios and poor stock performance reinforces the conclusion that Y-mAbs Therapeutics, Inc. is overvalued in its current state.